Abbott announces new data that shows artificial intelligence technology can help doctors better determine which patients are having a heart attack
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced that new research, published in the journal Circulation, found its algorithm could help doctors in hospital emergency rooms more accurately determine if someone is having a heart attack or not, so that they can receive faster treatments or be safely discharged.
Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data from OCREVUS® (ocrelizumab) trials in relapsing and primary progressive multiple sclerosis (MS). The analyses provide new insights into the biology of MS that advance the understanding of disease progression, with the goal of identifying and slowing disease progression as early as possible to preserve patient function over the long term.
Boehringer Ingelheim eExpands KRAS cancer program with Lupin's clinical stage MEK inhibitor compound
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin’s lead MEK inhibitor compound in combination with one of Boehringer Ingelheim’s innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
- Details
- Category: Novartis
Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into a global commercialization agreement for a proposed natalizumab biosimilar. The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-line treatment for adults with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have the genetic mutations of epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitutions.
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock (the "Shares") of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019
Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF patients
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, healthcare professionals (HCPs) and researchers.
In the fifty years prior, warfarin had been the standard of care for stroke prevention in atrial fibrillation (SPAF).
More Pharma News ...
- Pfizer invests half billion dollars to advance state-of-the-art gene therapy facility in Sanford, North Carolina
- FDA grants Fast Track designation for Farxiga in chronic kidney disease
- Amgen to acquire Otezla® for $13.4 billion in cash
- AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi
- Amgen and Allergan announce positive top-line results from comparative clinical study of ABP 798, biosimilar candidate to Rituxan® (rituximab)
- The Pfizer Foundation invests in 20 organizations tackling infectious diseases and antimicrobial resistance
- Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure